Ovid Therapeutics Inc（OVID）财务数据OVIDOvid Therapeutics Inc

Evaluating the bottom line, Ovid Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2141.61%, while the net margin is -2047.61%. These profitability ratios, combined with a Return on Equity (ROE) of -25.96%, provide a clear picture of how effectively OVID converts its operational activities into shareholder value.

In the context of the broader market, OVID competes directly with industry leaders such as AUTL and MPLT. With a market capitalization of $460.90M, it holds a significant position in the sector. When comparing efficiency, OVID's gross margin of 100.00% stands against AUTL's 57.61% and MPLT's N/A. Such benchmarking helps identify whether Ovid Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Ovid's financial performance shows a mixed picture with a gross margin of 100% in recent quarters, but significant net income losses, including -$16,988,000 in Q1 2026 and -$15,009,000 in Q2 2026, indicating ongoing financial struggles.